In video 1 of this three-part series, learn about the relevance of real-world evidence in COPD with underlying type 2 inflammation and how it can complement phase 3 clinical trial findings, with pulmonologist Dr. Mustafa Abdo.
In video 2 of this three-part series, learn about the rationale for a German real-world study of dupilumab in patients with COPD and underlying type 2 inflammation, and how it aims to complement clinical trial evidence, with pulmonologist Dr. Mustafa Abdo.
This symposium highlights type 2 inflammation as a key driver of chronic itch and the characteristic skin lesions of prurigo nodularis and evaluates the real-world implications of targeted therapies on clinical practice.
Professors Matthias Augustin and Sarina Elmariah evaluate how targeted therapies transform the management of prurigo nodularis, addressing the itch-scratch cycle and broader manifestations such as lesions.

Dr. Stella Lee and Profs. Peter Hellings and Wytske Fokkens discuss type 2 inflammation, partnering with patients to improve outcomes, and real-world data on biologic effectiveness in CRSwNP.